Novo Nordisk halts two heart-failure drug trials after earlier late-stage failure
Novo Nordisk stopped two trials of experimental cardiovascular drug ziltivekimab after an independent committee found a low likelihood of success. One heart-attack recovery trial remains active, with results expected in early 2027.
By DoomRadar · Published on DoomRadar . Updated .
How the effects could reach youConditional effects
What happened
The halted studies were testing ziltivekimab in heart-failure patients, and the decision followed an independent data monitoring committee assessment. [2]
References for this detail (1)
- Novo Nordisk (NYSE: NVO) Scraps Two Heart-Failure Drug Trials As Cardiovascular Pipeline Shrinksforeignpolicyjournal.com · Recorded source date: Sep 19, 2026, 1:47 AM UTC
An earlier late-stage trial failed to reduce major adverse cardiovascular events, according to the cited report. [2]
References for this detail (1)
- Novo Nordisk (NYSE: NVO) Scraps Two Heart-Failure Drug Trials As Cardiovascular Pipeline Shrinksforeignpolicyjournal.com · Recorded source date: Sep 19, 2026, 1:47 AM UTC
Novo Nordisk continues testing ziltivekimab in patients recovering from a heart attack, with results expected in the first half of 2027. [2]
References for this detail (1)
- Novo Nordisk (NYSE: NVO) Scraps Two Heart-Failure Drug Trials As Cardiovascular Pipeline Shrinksforeignpolicyjournal.com · Recorded source date: Sep 19, 2026, 1:47 AM UTC
The company’s shares and pipeline were discussed in the context of diversification beyond obesity and diabetes treatments. [2][1][3]
References for this detail (3)
- Novartis (NVS) and Ionis (IONS)' Big Cholesterol Bet Comes Up Short in Late-Stage Trialfinance.yahoo.com · Recorded source date: Sep 18, 2026, 10:31 PM UTC
- Novo Nordisk (NYSE: NVO) Scraps Two Heart-Failure Drug Trials As Cardiovascular Pipeline Shrinksforeignpolicyjournal.com · Recorded source date: Sep 19, 2026, 1:47 AM UTC
- Novo Nordisk (NVO) Pulls the Plug on Two More Heart Drug Trialsfinance.yahoo.com · Recorded source date: Sep 19, 2026, 5:47 AM UTC
Context from the sources
The cited report says the remaining heart-attack trial could provide a growth opportunity if successful, while another failure would further weaken the company’s pipeline-diversification strategy. [2]
Explore the sources and reporting timeline
3 source links · 2 domains
These counts describe the references, not independent confirmations. Different outlets can repeat the same original report.
Source timeline
Oldest to newest among the available source dates, not a chronology of the incident. Article publication dates come from the source; other recorded dates may reflect when a link was found.
- [1] Novartis (NVS) and Ionis (IONS)' Big Cholesterol Bet Comes Up Short in Late-Stage Trialfinance.yahoo.comReferenced for: detail 4
- [2] Novo Nordisk (NYSE: NVO) Scraps Two Heart-Failure Drug Trials As Cardiovascular Pipeline Shrinksforeignpolicyjournal.comReferenced for: detail 1, detail 2, detail 3, detail 4
- [3] Novo Nordisk (NVO) Pulls the Plug on Two More Heart Drug Trialsfinance.yahoo.comReferenced for: detail 4
What this could mean for you
No immediate public-safety effect is established; future cardiovascular treatment options could narrow if the remaining program also fails.
Stopping two trials reduces the number of development paths for the experimental drug.
Reported basis: [2] · The possible effect is interpretation.
Depends on: The remaining trial must also fail or be discontinued, and no alternative program must replace it.
Possible time frame: months, if those conditions hold.
Possible consequences, not a forecast. Their relevance depends on your location and the conditions above.
For your country
Choose a country to check how this event could affect you.
What changes the outlook
Risk increases if…
The remaining ziltivekimab trial fails to show cardiovascular benefit.
Novo Nordisk discontinues its remaining cardiovascular opportunity.
Pressure eases if…
The remaining heart-attack recovery trial produces positive results.
Another cardiovascular program replaces the halted studies.
Still unclear
The excerpts do not give the number of patients enrolled or the trial locations.
The sources do not establish any change to existing cardiovascular treatment access or prices.
Market implications
Market impact
Sources (3)
References for the reported details. Separate links do not necessarily mean independent confirmation.
Available excerpt
Novo Nordisk A/S (NYSE: NVO) has halted two additional clinical trials of its experimental cardiovascular drug ziltivekimab, dealing another blow to the Danish drugmaker’s diversification…A short excerpt from our source record; open the original for the full article.
First tracked by DoomRadar: . AI-assisted analysis · . Based on linked headlines and available excerpts. Methodology · Report an error.